Healthcare Business News

SCOTTSDALE, AZ–(Marketwire – July 12, 2010) –  Rural/Metro Corporation (NASDAQ: RURL) announced today that senior human resources executive Maureen Thompson, 49, has joined the Company to lead strategic and corporate human resources throughout the enterprise.

Michael P. DiMino, President and Chief Executive Officer, said, “Maureen is a highly regarded human resources leader with an extensive record of strategic and operational experience in large organizations across a variety of industries. She is a results-driven, operationally motivated leader who is adept at communication and collaboration at every level of an organization. We are very pleased to welcome her to Rural/Metro.”

In her role at Rural/Metro, Ms. Thompson will be responsible for all human resources leadership, strategy and direction, including employee relations, training, recruiting, compensation, benefits, organizational management, and policy and procedure development. She will report directly to the CEO.

Ms. Thompson has a demonstrated track record of working with large consumer product and retail organizations, including Retail HR Strategic Business Partner for The Goodyear Tire and Rubber Company, the world’s largest tire company with annual sales of $18 billion, from 2006 to 2009. From 2002 to 2006, she was Vice President of Human Resources for LESCO Inc., a $585 million public company that was the nation’s largest distributor of landscape and lawn care products (now an operating company of John Deere). Prior to that, Ms. Thompson was Vice President of Human Resources for Alamo Local Market Division, a division of ANC Retail Corporation, from 2000 to 2002.

“I am excited about this great opportunity and look forward to building a best-in-class human resources team that focuses on both strategic and tactical solutions that will support Rural/Metro’s organizational growth in the future,” Ms. Thompson said.

About Rural/Metro

Rural/Metro Corporation provides emergency and non-emergency ambulance services and private fire protection services in 20 states and approximately 400 communities throughout the United States. For more information, visit the Company’s web site at www.ruralmetro.com.

SAFE HARBOR PROVISIONS FOR FORWARD-LOOKING STATEMENTS

The foregoing reflects the Company’s views about its future financial condition, performance and other matters that constitute “forward-looking” statements as such term is defined by the federal securities laws. Many of these statements can be found by looking for words such as “believe,” “anticipate,” “expect,” “plan,” “intend,” “may,” “should,” “will likely result,” “continue,” “estimate,” “project,” “goals,” or similar words used herein in connection with any discussions of future operating or financial performance or business prospects. We may also make forward-looking statements in our earnings reports filed with the Securities and Exchange Commission, earnings calls and other investor communications. These forward-looking statements are subject to the safe harbor protection provided by federal securities laws. These forward-looking statements are subject to numerous risks, uncertainties and assumptions, including those relating to the Company’s future business prospects, future growth plans and future operating results. In addition, the Company may face risks and uncertainties related to other factors that are listed in its periodic reports filed under the Securities Exchange Act. Although the Company believes the expectations reflected in its forward-looking statements are based upon reasonable assumptions, because the statements are subject to risks and uncertainties, the Company can give no assurance that its expectations will be attained or that actual developments and results will not materially differ from those expressed or implied by the forward-looking statements. Readers are cautioned not to place undue reliance on the statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

(RURL/G)

NEWPORT BEACH, CA–(Marketwire – July 9, 2010) – Nationwide Health Properties, Inc. (NYSE: NHP) announced today that the Company will release its 2010 second quarter earnings on Monday, August 2, 2010 after the close of trading on the New York Stock Exchange. The Company will host a conference call on Tuesday, August 3, 2010 at 11:00 a.m. Pacific Time (2:00 p.m. Eastern Time) in order to present the Company’s financial performance and operating results for the quarter ended June 30, 2010.

The webcast can be accessed in the Investor Relations section of our website at www.nhp-reit.com. Participants may also join via teleconference by dialing (800) 573-4752 and referencing conference ID number 96821760. The international dial-in number is (617) 224-4324. The earnings release and any additional financial information that may be discussed on the webcast/conference call will also be available on our website. A digitized replay of the conference call will be available from 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) that day until 9:00 p.m. Pacific Time (Midnight Eastern Time), September 3, 2010. Callers can access the replay by dialing (888) 286-8010 or (617) 801-6888 and entering conference ID number 78550756. Webcast replays will also be available on our website for at least 12 months following the conference call.

Nationwide Health Properties, Inc. is a real estate investment trust (REIT) that invests primarily in healthcare real estate in the United States. As of March 31, 2010, the Company’s portfolio of properties, including mortgage loans and properties owned by unconsolidated joint ventures, totaled 606 properties among the following segments: 279 senior housing facilities, 197 skilled nursing facilities, 112 medical office buildings, 11 continuing care retirement communities and 7 specialty hospitals. For more information on Nationwide Health Properties, Inc., visit our website at http://www.nhp-reit.com.

NEW YORK, NY–(Marketwire – July 6, 2010) –  Healthnostics, Inc. (PINKSHEETS: HNSS), a medical and biotechnology analytics company, has agreed to acquire a medical manufacturing company on multi-year terms that include benchmarks of a first year profit target range of $300,000-$600,000 and a second year target range of $600,000-$900,000. These numbers do not include the benefits of reinvestment by the company in (a) manufacturing, (b) existing company products, and (c) reduction of outstanding shares through company purchases. As a result, the medical manufacturing profits can potentially have a multiplier effect on the Company’s earnings per share.

The Company will continue to provide additional details as its acquisition strategy continues to unfold.

“We are pleased to provide this acquisition update showing the significant benefit that can accrue for the Company and stockholders,” said Alan Grofe, President.

About Healthnostics

Healthnostics, Inc. is a medical and biotechnology analytics company that provides comprehensive patient clinical monitoring and risk management systems to acute care hospitals and utilizes its Internet portals to deliver medical and biotechnology resource information to industry professionals as well as to the general public. Healthnostics’ major products include: MedGuardian, a patient care monitoring and risk management system for hospitals that is fully Web-based; and through the MedBioWeb subsidiary, MedBioWorld™, one of the largest professional medical and biotechnology directory resource and reference portal sites on the Internet, and FamilyMedicalNet, a companion consumer healthcare information portal.

For further information please visit Healthnostics www.healthnostics.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com.

And visit us on Facebook at www.facebook.com/Healthnostics.

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

FORT LAUDERDALE, FL–(Marketwire – July 2, 2010) –  eDiets.com, Inc. (NASDAQ: DIET), a leading provider of convenient at-home diet, fitness and healthy lifestyle solutions, today announced that on June 28, 2010, it received notice from The Nasdaq Stock Market that the minimum bid price of the Company’s common stock closed below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with Nasdaq’s listing rules (Rule 5550(a)(2)).

In accordance with the rules, the Company has 180 calendar days, or until December 27, 2010, to regain compliance. If at any time before that date the bid price of the Company’s common stock closes at $1.00 per share or more for at least 10 consecutive business days, Nasdaq will provide written notification that the Company complies with the rules (Rule 5810(c)(3)(A)).

If compliance is not achieved by December 27, 2010, the Company will be eligible for an additional compliance period of 180 days provided that it meets The Nasdaq Capital Market initial listing criteria (Rule 5505), with the exception of the bid price requirement. If the Company is not eligible for an additional compliance period, Nasdaq will provide written notification that the Company’s securities will be delisted. At that time, the Company may appeal Nasdaq’s determination that the Company’s common stock will be delisted from The Nasdaq Capital Market.

About eDiets

eDiets.com, Inc. is a leading provider of personalized nutrition, fitness and weight-loss programs. eDiets currently features its award-winning, fresh-prepared diet meal delivery service as one of the more than 20 popular diet plans sold directly to members on its flagship site, www.eDiets.com. The company also provides a broad range of customized wellness and weight management solutions for Fortune 500 clients. eDiets.com’s unique infrastructure offers businesses, as well as individuals, an end-to-end solution strategically tailored to meet its customers’ specific goals of achieving a healthy lifestyle. For more information, please call 310-954-1105 or visit www.eDiets.com.

Safe Harbor Statement
Statements which are not historical in nature are forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements. These risks and uncertainties include, among others, that we will not be able to obtain sufficient and/or acceptable outside financing (when and if required); changes in general economic and business conditions; changes in product acceptance by consumers; a decline in the effectiveness of sales and marketing efforts; loss of market share and pressure on prices resulting from competition; significant investments in our technology platform, marketing plans, and product development to remain competitive with other online providers of healthy living and weight loss plans, many of which may be found to offer superior and more varied features than our plans and may also be offered for free; volatility in the advertising markets; any delay, disruption, or suspension of our supply of prepared meals from our vendor; changes in consumer preferences and discretionary spending; product liability and other risks from the sale of ingested products; regulatory actions affecting our marketing activities; and the outcome of litigation pending against us. For additional information regarding these and other risks and uncertainties associated with eDiets.com’s business, reference is made to our Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed from time to time with the Securities and Exchange Commission. All forward-looking statements are current only as of the date on which such statements are made. We do not undertake any obligation to publicly update any forward-looking statements.

MADISON, WI–(Marketwire – July 1, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, announced today that it will release its 2010 second quarter financial results on Thursday, July 29, 2010 at 3:00 p.m. CDT.

TomoTherapy will hold an investment community conference call on Thursday, July 29, 2010 beginning at 4:00 p.m. CDT. Fred Robertson, M.D., CEO, and Thomas Powell, CFO, will review second quarter performance and discuss the company’s strategies. To join the conference call, dial 1-800-260-8140 (international 1-617-614-3672) and enter passcode 35309628. A replay of the conference call will be available at 7:00 p.m. CDT on July 29, 2010, through 11:59 p.m. CDT on August 5, 2010. To access the replay, dial 1-888-286-8010 (international 1-617-801-6888) and enter passcode 64325104.

For individual investors, a live Webcast of the conference call will be available on the Investor Relations page of TomoTherapy.com. Institutional investors can access the Webcast through a password-protected site, www.streetevents.com. An archived Webcast of TomoTherapy’s conference call will be available for two weeks.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, Hi·Art, TomoHD, TomoMobile and the TomoTherapy logo are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

NEW YORK, NY–(Marketwire – July 1, 2010) –  Allied Healthcare International Inc. (NASDAQ: AHCI) (AIM: AHI) (“Allied”), a leading provider of flexible healthcare staffing services in the United Kingdom, announces today that it has requested the cancellation of admission to trading of its depository interests on the Alternative Investment Market (AIM) of the London Stock Exchange. Cancellation will become effective as of 7:00 a.m., U.K. time, on August 20, 2010 (the “Effective Time”). The depository interests will trade on AIM through the close of business on August 19, 2010. Each depository interest represents one share of common stock of Allied.

The shares of common stock of Allied will continue to trade on the Nasdaq Global Select Market after the cancellation of admission to trading on AIM of the depository interests.

Allied’s depository interests were admitted to trading on AIM in December 2005 in the expectation (among other reasons) that the quotation would provide an additional source of liquidity for investors who wished to own an equity position in Allied. Allied also anticipated that the admission to trading on AIM of its depository interests would enable it to access the capital markets in the U.K. and provide it with an enhanced ability to undertake acquisitions. However, there have never been more than ten holders of depository interests at any one time and there are currently only eight holders of depository interests. As a result, Allied has not realized the benefits it anticipated at the time of admission. In light of this and the costs and additional regulatory burdens associated with continued admission of its depository interests, the board of directors of Allied has determined to request the cancellation of admission to trading on AIM of its depository interests as of the Effective Time.

At the Effective Time, the Deed that established the depository interests will be terminated and the depository interests will cease to exist. Prior to the Effective Time, holders of depository interests will be able to trade their depository interests on AIM or transfer their depository interests into an identical number of shares of common stock of Allied. In the event that any holder of depository interests has not transferred its depository interests into shares of common stock prior to the Effective Time, at the Effective Time the depository will cause any holder of then-outstanding depository interests to be registered on the stockholders’ list of Allied as a holder of an identical number of shares of common stock of Allied. Allied will send to the current holders of depository interests a letter explaining their options for converting depository interests into shares of common stock.

About Allied Healthcare International Inc.

Allied Healthcare International Inc. is a leading provider of flexible healthcare staffing services in the United Kingdom. Allied operates a community-based network of over 110 branches with the capacity to provide carers (known as home health aides in the U.S.), nurses, and specialized medical personnel to locations covering approximately 90% of the U.K. population. Allied meets the needs of private patients, community care, nursing and care homes, and hospitals. For more news and information please visit: www.alliedhealthcare.com.

Forward-Looking Statements

Certain statements contained in this news release may be forward-looking statements. These forward-looking statements are based on current expectations and projections about future events. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Factors that could cause actual results to differ from those implied by the forward-looking statements include: general economic and market conditions; Allied’s ability to continue to recruit and retain flexible healthcare staff; Allied’s ability to enter into contracts with local government social services departments, NHS Trusts, hospitals, other healthcare facility clients and private clients on terms attractive to Allied; the general level of demand for healthcare and social care; dependence on the proper functioning of Allied’s information systems; the effect of existing or future government regulation of the healthcare and social care industry, and Allied’s ability to comply with these regulations; the impact of medical malpractice and other claims asserted against Allied; the effect of regulatory change that may apply to Allied and that may increase costs and reduce revenues and profitability; Allied’s ability to use net operating loss carry forwards to offset net income; the effect that fluctuations in foreign currency exchange rates may have on our dollar-denominated results of operations; and the impairment of goodwill, of which Allied has a substantial amount on the balance sheet, may have the effect of decreasing earnings or increasing losses. Other factors that could cause actual results to differ from those implied by the forward-looking statements in this press release include those described in Allied’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. Allied undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. 

TAMARAC, FL–(Marketwire – July 1, 2010) –  AcuMedSpa Holdings, Inc. (PINKSHEETS: AMSZ), a provider of Medical Aesthetic, Spa and Acupuncture services, would like to address an erroneous filing made to raise the authorized shares.

A filing dated June 25, 2010 was made with the state of Nevada to raise the authorized shares of AcuMedSpa from its current 150 million shares to 300 million shares. This action was done erroneously and was never intended to be filed. AcuMedSpa has rescinded the incorrect filing and expects the State of Nevada website to reflect this action shortly. The correct authorized shares total should be 150 million shares.

The company does not have the authority to raise the authorized shares without majority shareholder approval. Recently AcuMedSpa reformed its share structure by reducing both the authorized shares and the outstanding shares. These changes were intended to give all major decision making power to the shareholders. Any significant share structure decisions such as raising the authorized shares, share issuances, and stock splits of any kind etc. now require the consent of a majority of shareholders by proxy vote.

“Obviously raising the authorized shares after just having lowered them was not by design,” stated AcuMedSpa Holdings President Gregory Antoine. “Just last week we reiterated in our press releases that moves like this cannot be done without consent from our shareholders. This was a regrettable internal communication error on our part. Our commitment to our shareholders has never wavered and we will continue to press forward in our efforts to continue building a strong company.”

Please follow our progress on twitter: http://twitter.com/acumedinc

For additional info please visit our website: http://www.acumedspa.com/

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements as a result of various factors, and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and AcuMedSpa Holdings, Inc. takes no obligation to update such statements.  

WINNIPEG, MANITOBA–(Marketwire – June 30, 2010) – DiaMedica Inc. (TSX VENTURE:DMA) (“DiaMedica” or the “Company”), is pleased to announce the completion today of its $2.26 million short form prospectus offering of units (the “Offering”) and its previously announced acquisition (the “Acquisition”) of Sanomune Inc., a privately held biopharmaceutical company focused on neurological disorders (“Sanomune”). 

The Offering

Pursuant to the completion of the Offering, DiaMedica has issued a total of 5,650,000 units (each a “Unit“) at a price of $0.40 per Unit for aggregate gross proceeds of $2.26 million. Each Unit is comprised of one common share in the capital of the Company (each a “Common Share“) and one Common Share purchase warrant (each a “Warrant“), with each Warrant entitling the holder thereof to acquire a further Common Share until the second anniversary of the closing of the Offering. The expiry date of the Warrants is subject to acceleration if the volume-weighted average trading price of the Common Shares on the TSX Venture Exchange (the “TSX-V“) exceeds $0.75 per share for a period of 10 consecutive trading days. 

The Offering was led by Bolder Investment Partners, Ltd., as agent (“Bolder”). In connection with the completion of the Offering, Bolder exercised its agent’s option to increase the size of the Offering by 13%, or 650,000 Units. 

The net proceeds of the Offering will be used to fund DiaMedica’s ongoing research and development programs, including planned pre-clinical trials for our lead products, and for general working capital purposes. 

As compensation for its services as agent, Bolder received a cash commission of $226,000, and received broker warrants to acquire up to 565,000 Common Shares exercisable at the price of $0.40 per share at any time on or prior to June 30, 2011.

The Acquisition

Pursuant to the completion of the Sanomune Acquisition, DiaMedica has issued a total of 12,807,377 Common Shares to Sanomune shareholders as consideration for all of the issued and outstanding shares of Sanomune.

“With the completion of this financing and the strategic acquisition of Sanomune, we have brought together two of Canada’s Top 10™ Life Sciences Companies,” stated Mr. Rick Pauls, President and Chief Executive Officer of DiaMedica. “This acquisition allows us to take advantage of a unique opportunity to strengthen our patent portfolio and expand into neurological and autoimmune disorders targeted by our lead program, DM-99/199, which has demonstrated neural protection (protects brain cells) and neural cell proliferation (creates brain cells)”.

As a result of the Acquisition, in addition to Sanomune’s lead compound, SAN-61, DiaMedica also acquires a panel of monoclonal antibodies that trigger the inhibition of glycogen synthase kinase 3 beta (GSK-3ß). GSK-3ß plays an important role as a regulatory switch for numerous cell-signaling pathways and has been linked to diabetes, cancer, infectious diseases and a variety of neurological disorders. It is anticipated that the monoclonal antibody program will compliment DiaMedica’s DM-99/199 program, which has also been shown to have GSK-3ß inhibiting properties.

As announced in its April 20, 2010 press release, DiaMedica obtained the required minority shareholder approval (the “Minority Approval”) for the Acquisition under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”), by securing written consents to the transaction from shareholders representing approximately 65% of the Common Shares held by parties eligible to vote for approval of the transaction under Part 8 of MI 61-101. This is in excess of the simple majority requirement (i.e., 50%+1) set out in MI 61-101 for such Minority Approval. 

In addition to the related parties described in DiaMedica’s February 18, 2010 press release regarding the Acquisition (each a “Related Party” and collectively, the “Related Parties”), Common Shares held by two investment funds, Manitoba Science & Technology Fund (“MST”) and Crocus Investment Fund (“CIF”) were also excluded for the purposes of obtaining Minority Approval for the Acquisition. MST and CIF each hold approximately 24.75% of the voting common shares of Genesys Ventures Inc., a Related Party, and are therefore each “a related party of an interested party” as described in MI 61-101. Immediately prior to the completion of the Acquisition and the Offering, the Related Parties, in the aggregate, beneficially owned, or exercised control or direction over, a total of 5,493,523 Common Shares, or 28.60% of the total issued and outstanding Common Shares. To the knowledge of the Company, based on public filings by each of MST and CIF, immediately prior to the completion of the Acquisition and the Offering, MST and CIF held, in the aggregate, a total of 3,065,764 Common Shares, or 15.96% of the total issued and outstanding Common Shares.

Management Changes

DiaMedica further announces the appointment of Mr. Pauls to the full-time position of President and Chief Executive Officer and the appointment of Dr. Mark Williams to Vice-President, Research. Dr. Stephen Waters has resigned from his interim role as Executive Vice-President and Interim Chief Scientific Officer.

Mr. Pauls, who has been an active board member since 2005, and is currently the Chairman of the Board of DiaMedica, has served as the acting President and Chief Executive Officer of the Company since July 2009. Mr. Pauls was previously the Managing Director of CentreStone Ventures Inc., a life sciences venture capital fund which he was involved with from inception. While with CentreStone, Mr. Pauls led investments in Orasi Medical Inc., winner of the Red Herring Global 100; LED Medical Inc., winner of Red Herring Canada 50 award in the Health category; as well as DiaMedica and Sanomune, both named among Canada’s Top 10™ Life Sciences Companies. Prior to his role with CentreStone, Mr. Pauls was employed by Centara Corporation, another early stage venture capital fund.

“We would like to express our gratitude to Dr. Stephen Waters for his valuable contributions to our strategic planning efforts and we look forward to working with him as a consultant,” continued Mr. Pauls. “The Board of Directors of DiaMedica joins me in thanking Dr. Waters for his efforts, and we wish him continued success in his future endeavors”.

In conjunction with these management changes, the Board of Directors has approved a grant of 457,500 stock options to certain directors, executives and employees under the terms of the Company’s stock option plan. The options have an exercise price of $0.42 per share and are exercisable for a period of 5 years. This grant of such options is subject to acceptance by the TSX-V.

Please visit DiaMedica’s new company website at www.diamedica.com.

About DiaMedica and Sanomune

DiaMedica is a biopharmaceutical company, focused on developing novel treatments for diabetes and neurological disorders. The Company’s diabetes program is based on a critical liver nerve signaling mechanism involved in enhancing insulin sensitivity after meal consumption. Two of DiaMedica’s products have demonstrated human efficacy in lowering blood sugar levels in diabetics based on this novel nerve signaling mechanism.

As a result of the Sanomune Acquisition, DiaMedica plans to expand its DM-199 program into neurological and autoimmune disorders. Sanomune has demonstrated that its lead compound, SAN-61, a naturally occurring protein, confers neural protection (protects brain cells) and triggers neural stem cell proliferation (creates brain cells) for the treatment of numerous neurological disorders including Alzheimer’s disease. DiaMedica has also acquired from Sanomune a panel of monoclonal antibodies targeting diabetes, neurological disorders and cancers through the inhibition of GSK-3ß.

Both DiaMedica and Sanomune were recognized as one of Canada’s Top 10™ Life Sciences Companies in 2008/2009. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”.

For further information please visit www.diamedica.com.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations.
These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our acquisition of Sanomune may be found in our press releases dated February 18, 2010 and April 20, 2010.

BOCA RATON, FL–(Marketwire – June 29, 2010) – Banyan Corporation (PINKSHEETS: BNYN) announced that its board of directors has agreed to the formation of a new operating unit of the company called “America’s Dentist.”

This operating division will focus on the multi-billion dollar dental industry and is establishing itself to provide marketing, finance, practice management and branding to the dental community. The company feels that it will be able to bring significant value added to a broad array of dental practices.

Banyan Corporation believes it can leverage off its significant experience with Chiropractic USA, as well as with its existing operations in its diagnostic imaging business, to move into the dental arena.

About Banyan Corporation:

Banyan Corporation is a publicly traded holding company focused on investing in and building a network of operating subsidiaries engaged in various innovative businesses. Currently the company’s subsidiaries, Premier Medical Group, Inc. and affiliated companies, provide diagnostic testing services to physicians nationwide.

This Press Release contains or incorporates by reference forward-looking statements including certain information with respect to plans and strategies of Banyan Corporation. For this purpose, any statements contained herein or incorporated herein by references that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “suggests,” “anticipates,” “plans,” “expects,” and similar expressions are intended to identify forward-looking statements. There are a number of events or actual results of Banyan Corporation operations that could differ materially from those indicated by such forward-looking statements.

TORONTO, ONTARIO–(Marketwire – June 28, 2010) – FMX Ventures Inc. (the “Company“) (TSX VENTURE:FXX.H)announced today that, subject to regulatory approval, it has appointed Mr. Carmelo Marrelli as its Chief Financial Officer. Mr. Marrelli replaces Jon Kelly who has resigned to pursue other interests. Mr. Kelly served as Chief Financial Officer of the Company prior to the sale of its orthotics business in 2007 and assisted with the Company’s transition from an operating company to its current form. The board of directors of the Company wishes to thank Mr. Kelly for his contributions.

Mr. Marrelli holds a Bachelor of Commerce degree from the University of Toronto and is a qualified Chartered Accountant and Certified General Accountant. Mr. Marrelli is currently President of Marrelli Support Services, a bookkeeping firm based in Toronto, Ontario.

Number of Common Shares Outstanding – 3,934,296

WASHINGTON, DC and WILLIAMSBURG, VA–(Marketwire – June 28, 2010) –  GuideStar, the leading source of nonprofit information, encourages any exempt organization whose fiscal year ends June 30 to verify that it is compliant with IRS reporting requirements in order to maintain its exemption.

Most tax-exempt organizations except churches are required to file an annual information return (IRS Form 990-N, 990-EZ, 990, or 990-PF). Organizations required to file that fail to do so for three consecutive years will automatically lose tax-exempt status, as mandated by a provision of the Pension Protection Act of 2006. 

The deadline for filing Form 990 and its variants is determined by the end of the filing organization’s fiscal year. The filing deadline for an organization whose fiscal year ends on June 30, 2010, is November 15, 2010. 

“The first time the revocation provision of the Pension Protection Act was put in effect was last May, when returns for organizations whose fiscal year ended December 31, 2009, were due,” said Bob Ottenhoff, GuideStar’s president and CEO. “We learned then that thousands of nonprofits, particularly smaller ones, did not realize they needed to file and were at risk of losing their exemptions. That’s why GuideStar created a nonprofit resource center about the revocations. Nonprofits can use the resource center to stay up to date on what they must do in terms of filing an annual information return.”

An organization’s annual gross revenue and assets determine which version of the 990 it must file. Filing extensions are available for Forms 990-EZ, 990, and 990-PF, but not for Form 990-N. (See the accompanying table.)

GuideStar’s nonprofit resource center provides an overview of the revocations issue and several quick links, including ones to a Form 990-N filing status database, the mechanics of filing Form 990-N, filing exceptions, filing thresholds, filing deadlines and extensions, and IRS and GuideStar revocation FAQs. The resource center is updated as new developments related to the revocations occur.

“We hope every exempt organization will use these resources to ensure that they are not at risk of losing their exemptions for failure to file an annual return,” Ottenhoff said. “Nonprofits play vital roles in our society, and losing tax-exempt status will hurt not only the organizations but also the causes and people they serve.” 

About GuideStar

GuideStar, www.guidestar.org, connects people and organizations with information on the programs and finances of more than 1.8 million IRS-recognized nonprofits. GuideStar serves a wide audience inside and outside the nonprofit sector, including individual donors, nonprofit leaders, grantmakers, government officials, academic researchers, and the media.

Click here to see all recent news from this company

ATLANTA, GA–(Marketwire – June 28, 2010) – ALR Technologies Inc. (OTCBB: ALRT) announces the appointment of Lawrence (Larry) Weinstein to be President and Chief Operating Officer effective July 1, 2010, replacing Sidney Chan who will become Chairman and Chief Executive Officer. Stan Cruitt is retiring as Chairman of the Company.

Larry has extensive experience in the development and launch of medical products. His experience includes 11 years with Cordis Corporation (a Johnson & Johnson company), 6 years with DHD Healthcare Corporation and most recently, 9 years with Pari Respiratory Equipment. He is leaving Pari as Senior Vice President of Operations at PRE Holding, Inc. and as President, Hydrate, Inc.

Mr. Chan says that, “Larry Weinstein brings a skill set and experience that will be invaluable as the company introduces the ALRT Health-e-Connect (HeC) monitoring system. Our product will be invaluable for the healthcare industry to achieve better health outcomes and contain costs.”

About ALR Technologies Inc.
ALRT Health-e-Connect (HeC) System is the principal product of the Company. HeC is a web-based application for medical professionals to improve compliance and adherence of care plans of patients in their homes. HeC is programmed to assist healthcare providers caring for diabetes patients. The platform will be expanded to cover patients with other chronic diseases. More information on ALR Technologies and its products can be found at http://www.alrt.com. 

This release contains certain “forward-looking statements” relating to ALR Technologies’ business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words “estimate,” “expect,” “anticipate,” “believe” and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company’s quarterly filings with the Securities Exchange Commission.